Pieris Pharmaceuticals, Inc. Stock price

Equities

PIRS

US7207951036

Biotechnology & Medical Research

Market Closed - Nasdaq 04:00:00 2024-03-27 pm EDT 5-day change 1st Jan Change
0.1937 USD +3.03% Intraday chart for Pieris Pharmaceuticals, Inc. -7.76% +6.43%
Sales 2023 * 31.98M Sales 2024 * 6.62M Capitalization 19.15M
Net income 2023 * -28M Net income 2024 * -17M EV / Sales 2023 * 0.6 x
Net cash position 2023 * - Net cash position 2024 * - EV / Sales 2024 * 2.89 x
P/E ratio 2023 *
-0.55 x
P/E ratio 2024 *
-0.97 x
Employees 136
Yield 2023 *
-
Yield 2024 *
-
Free-Float 92.55%
More Fundamentals * Assessed data
Dynamic Chart

Latest transcript on Pieris Pharmaceuticals, Inc.

1 day+3.03%
1 week-7.76%
Current month+17.32%
1 month+20.61%
3 months+5.33%
6 months-34.87%
Current year+6.43%
More quotes
1 week
0.18
Extreme 0.179
0.22
1 month
0.16
Extreme 0.155
0.28
Current year
0.15
Extreme 0.1485
0.28
1 year
0.14
Extreme 0.1361
1.29
3 years
0.14
Extreme 0.1361
6.15
5 years
0.14
Extreme 0.1361
6.15
10 years
0.14
Extreme 0.1361
9.75
More quotes
Managers TitleAgeSince
Chief Executive Officer 48 09-12-31
Director of Finance/CFO 49 17-11-30
Chief Tech/Sci/R&D Officer - 16-12-31
Members of the board TitleAgeSince
Director/Board Member 59 16-09-19
Chairman 70 17-05-21
Director/Board Member 63 14-12-16
More insiders
Date Price Change Volume
24-03-27 0.1937 +3.03% 1,238,321
24-03-26 0.188 +3.47% 358,787
24-03-25 0.1817 -9.15% 2,968,260
24-03-22 0.2 +0.05% 735,308
24-03-21 0.1999 -4.81% 650,589

Delayed Quote Nasdaq, March 27, 2024 at 04:00 pm EDT

More quotes
Pieris Pharmaceuticals, Inc. is a clinical-stage biotechnology company that discovers and develops Anticalin-based drugs to target validated disease pathways. The Company's clinical pipeline includes an inhaled IL-4Ra antagonist Anticalin protein to treat asthma, an immuno-oncology (IO), bispecific targeting HER2 and 4-1BB, and an IO bispecific targeting PD-L1 and 4-1BB. Its lead respiratory Anticalin based drug candidate, elarekibep, antagonizes IL-4Ra, thereby inhibiting IL-4 and IL-13, two cytokines, which are small proteins mediating signaling between cells within the human body, known to be key mediators in the inflammatory cascade that drive the pathogenesis of asthma and other inflammatory diseases. Its IO portfolio also includes additional drug candidates beyond PRS-344/S095012 that are multi-specific Anticalin-based fusion proteins designed to engage immunomodulatory targets, comprising a variety of multifunctional biotherapeutics.
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
C
More Ratings
Sell
Consensus
Buy
Mean consensus
HOLD
Number of Analysts
1
Last Close Price
0.1937
Average target price
-
Consensus
  1. Stock
  2. Equities
  3. Stock Pieris Pharmaceuticals, Inc. - Nasdaq